Pacific Biosciences Of California (PACB) Cash from Investing Activities (2010 - 2026)

Pacific Biosciences Of California's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $35.9 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 20.73% year-over-year to $35.9 million; the TTM figure through Mar 2026 stood at $106.1 million (down 47.84% YoY), while the FY2025 annual figure was $115.4 million, down 6.9% from the prior year.
• Cash from Investing Activities was $35.9 million for Q1 2026 at Pacific Biosciences Of California, up from $26.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $242.3 million in Q3 2023 to a low of -$98.6 million in Q2 2023.
• Historically, Cash from Investing Activities has averaged $23.3 million across 5 years, with a median of $26.0 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities soared 414.72% in 2022, then slumped 272.53% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at $80.4 million in 2022, then plunged by 182.8% to -$66.6 million in 2023, then soared by 187.48% to $58.2 million in 2024, then plunged by 55.31% to $26.0 million in 2025, then surged by 37.77% to $35.9 million in 2026.
• The last three Cash from Investing Activities figures came in at $35.9 million (Q1 2026), $26.0 million (Q4 2025), and $18.9 million (Q3 2025), per Business Quant data.